

Both parties agree to push back Xarelto bellwether trials again

First bellwether trial in Xarelto multidistrict litigation now scheduled to begin in April 2017

SAN DIEGO, CALIF., UNITED STATES, February 24, 2017 /EINPresswire.com/ -- Plaintiffs in the four lawsuits picked to be tried first in the Xarelto multidistrict litigation (MDL) will have to wait a little longer to see their day in court. The four bellwether trials were pushed back another month at the behest of both plaintiffs and defendants.

The four [Xarelto bellwether trials were initially set to begin](#) this month in Louisiana's Eastern District. They were rescheduled to begin in March after the NBA All-Star Games were moved to New Orleans in response to North Carolina's controversial "bathroom bill."

At both parties' request, the bellwethers were delayed again and the first trial will now begin in April. The second, third, and fourth trials are scheduled to begin in the months following.

District Judge Eldon E. Fallon issued Case Management Order 2D on Jan. 30, laying out the bellwether trial schedule as follows:

- First trial -- April 24, 2017 in the Eastern District of Louisiana
- Second trial -- May 30, 2017 in the Eastern District of Louisiana
- Third trial -- To Be Set in June 2017 in the Southern District of Mississippi
- Fourth trial -- To Be Set in July 2017 in the Northern District of Texas

The following cases were chosen as bellwethers:

1. Boudreaux, Jr. et al v. Janssen Research & Development LLC et al (2:14-cv-02720)
2. Orr et al v. Janssen Research & Development LLC et al (2:15-cv-03708)
3. Mingo v. Janssen Research & Development LLC et al (2:15-cv-03469)
4. Henry v. Jansen Research & Development LLC et al (2:15-cv-00224)

There were over 15,000 cases involved in the massive Xarelto MDL as of Feb. 15.

The lawsuits stem from allegations that the anticoagulant Xarelto could cause uncontrollable bleeding



in some people. They accuse the drug's manufacturers -- Bayer Healthcare and Johnson & Johnson subsidiary Janssen Pharmaceuticals -- of failing to warn about Xarelto's potential risks.

The first bellwether trial involves a Louisiana man with atrial fibrillation, who took Xarelto and suffered life-threatening gastrointestinal bleeding.

Joseph Boudreaux Jr. took Xarelto for just under one month in 2014 before he was hospitalized for severe internal bleeding, according to the lawsuit.

Boudreaux needed several blood transfusions and was hospitalized for five days as a result of his Xarelto bleeding episode. He then required follow-up medical treatment following his stay in the hospital, court documents indicated.

Boudreaux filed a Xarelto lawsuit against Janssen and Bayer in December 2014, accusing the two manufacturers of concealing their knowledge of Xarelto's defects from physicians and patients like himself.

His attorneys are set to square off against defendants Janssen and Bayer on April 24, 2017 in New Orleans.

Xarelto patients who experienced side effects like uncontrollable bleeding may be able to file [Xarelto lawsuits](#) of their own. Schmidt National Law Group is currently seeking claimants and is in the process of filing claims related to Xarelto and uncontrollable bleeding. Contact us today at 1-800-214-1010 or visit our website to learn more.

About Schmidt National Law Group

Schmidt National Law Group is a personal injury firm located in San Diego, Calif. Its team of experienced attorneys represents victims of all types of injuries, including those harmed by pharmaceutical drugs and medical devices.

Schmidt National Law Group's team of attorneys, medical professionals, writers, and case managers fight every day for the rights of the injured. Martin Schmidt, a trial attorney with 30 years experience, has been recognized as a leading personal injury attorney and was chosen as one of the "Top 100 Trial Lawyers" by the American Association for Justice in 2015 and 2016.

Contact Us

Schmidt National Law Group
<http://www.nationalinjuryhelp.com/>
4241 Jutland Drive, Suite 200, San Diego CA, 92117
1-800-214-1010

Melissa Beltz
Schmidt National Law Group
800-214-1010 Ext. 370
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist

you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2017 IPD Group, Inc. All Right Reserved.